In what would be the largest value licensing deal of 2005 so far, Pfizer has agreed to develop, manufacture and commercialise Coley Pharmaceutical Group's Phase II oligonucleotide therapeutic, ProMune#8482; (CpG 7909), which has broad applicability as an anticancer therapy. This article examines the motivations of both companies for signing the deal.